IL-23 inhibitor

This page covers all IL-23 inhibitor drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting IL-23 (interleukin-23), IL-23 p19 subunit, IL-23R.

Targets

IL-23 (interleukin-23) · IL-23 p19 subunit · IL-23R

Phase 3 pipeline (2)

• IL-23 Therapy · Weill Medical College of Cornell University · Immunology
  IL-23 therapy inhibits the IL-23 signaling pathway to reduce pathogenic T-cell responses and inflammatory cytokine production.
• risankizumab IV · AbbVie · Immunology
  Risankizumab is a humanized monoclonal antibody that selectively binds to and blocks the interleukin-23 (IL-23) p19 subunit.

Phase 2 pipeline (1)

• Any biologic treatment for psoriasis · Bristol-Myers Squibb · Immunology
  Tildrakizumab blocks the interaction between interleukin-23 (IL-23) and its receptor, reducing inflammation in the body.